Reportedly, an experimental Amgen Inc (AMGN) drug meant for a specific genetic mutation reduced tumors in 32% of advanced lung cancer patients and 7% with those suffering from colon cancer in an early-stage trial. The drug sotorasib was given to lung cancer patients for 6.3 months and 4 months for colorectal cancer patients before their disease worsened. The oral dose of medication is formulated to target a mutated form of a gene known as KRAS, occurring in about 13% of the most common form of lung cancer, the non-small cell lung cancers (NSCLC). The above mutation is also found in 1% to 3% of colorectal and other cancers. Sotorasib targets gene mutations leading to cancer, irrespective of which organ the disease originated.
As per the research and dosage, among the 59 patients, 32% had a partial reaction to the drug, with tumor reduction by at least 30%, and the remaining percentage experienced slow response or stable disease. 42 patients with colorectal cancer experienced 7% had tumor reduction, and 74% had stable disease.
Gregory Friberg, Amgen’s head of oncology global development stated, “These are patients that have very few options. They were on a third or fourth line of therapy.”
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.
